Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
51,252,511
-
Total 13F shares
-
5,136,537
-
Share change
-
-366,621
-
Total reported value
-
$12,262,078
-
Price per share
-
$2.39
-
Number of holders
-
28
-
Value change
-
-$1,134,647
-
Number of buys
-
7
-
Number of sells
-
10
Institutional Holders of Protara Therapeutics, Inc. - Common Stock (TARA) as of Q2 2023
As of 30 Jun 2023,
Protara Therapeutics, Inc. - Common Stock (TARA) was held by
28 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,136,537 shares.
The largest 10 holders included
Opaleye Management Inc., ORBIMED ADVISORS LLC, VANGUARD GROUP INC, Boxer Capital, LLC, BAKER BROS. ADVISORS LP, Ikarian Capital, LLC, Privium Fund Management (UK) Ltd, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, and BRIDGEWAY CAPITAL MANAGEMENT, LLC.
This page lists
28
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.